Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.
about
Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunizationAlphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challengeAlphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.Alphavirus-based vaccinesHigh-Resolution X-Ray Structure and Functional Analysis of the Murine Norovirus 1 Capsid Protein Protruding DomainVirus like particle-based vaccines against emerging infectious disease viruses.Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection.Vaccine against norovirus.Identification of cross-reactive norovirus CD4+ T cell epitopesChimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice.Comparison of immune responses to gonococcal PorB delivered as outer membrane vesicles, recombinant protein, or Venezuelan equine encephalitis virus replicon particles.Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice.Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs.Heterologous gene expression from transmissible gastroenteritis virus replicon particles.Norovirus GII.4 strain antigenic variationVaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles.Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectivesVenezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particlesNorovirus capture with histo-blood group antigens reveals novel virus-ligand interactions.Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle.The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.Therapeutic and prophylactic applications of alphavirus vectors.Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects.Comparative evaluation of recombinant protein production in different biofactories: the green perspective.Norwalk virus-like particles as vaccines.Glycosphingolipids as receptors for non-enveloped viruses.Worldwide molecular epidemiology of norovirus infection.Self-replicating alphavirus RNA vaccines.A human dendritic cell subset receptive to the Venezuelan equine encephalitis virus-derived replicon particle constitutively expresses IL-32.The application of virus-like particles as vaccines and biological vehicles.Prospects and Challenges in the Development of a Norovirus Vaccine.
P2860
Q24634730-FA6EAB29-50D9-45F0-9F51-CB1C846D5DC0Q24657762-478CA95F-272A-4915-AAEA-EF0EC37EF81DQ24796792-1ABDD57F-FA42-43D4-BD37-C5671891B786Q26994724-FE1B8BC9-FD8A-4297-94F3-06BCD3357D17Q27660321-81828BFA-8C1A-4E6E-973F-ABAA2F73A184Q30249025-571D7AFF-9E21-4718-B20C-99D5CC99A0FDQ33392684-45276E51-BCDB-4F52-B73B-CDCFA3C228F0Q33578075-E7919DDC-1C54-48AE-B271-AF97C726571CQ33614545-771FF7F8-5141-4229-A4D0-69C85F98F35EQ33743992-A86FA1CC-5C2F-4857-B3BC-27515F59C2D8Q33962224-F689AF4F-8C42-49B1-906C-658C5BA9FD90Q34111792-CDE5EACC-A1D9-4775-9D34-925BB676396BQ34142905-CBA22AE5-ADD6-4FD1-8E34-217FFEBF5557Q34228602-94AC09EC-BE86-4F5B-9B4F-883C342792B6Q34328584-988EBA36-4B55-4AB9-B462-507B4C29C1B0Q34457831-D3848698-10D5-41E7-BCF6-C5DEB915FA80Q34491679-3B55A43F-8662-48DC-A0F4-3A3BCAA04962Q34742846-FC96FC03-41E8-422A-8CCC-77907C196F6EQ35656636-AED98E0E-44C6-4CFD-82D2-6E402B967B28Q36149102-474266AC-07FE-4E39-91D2-91DA29F08F6AQ36275589-33D31592-BDED-4B02-90D3-A484A18F3821Q36315159-B812FDD4-4EA4-42CA-ADD0-1E1ECD93307FQ36445296-3DEA8F8A-269C-4782-BF26-BFA51F624FC1Q36458651-FEB81342-3E3C-4759-B589-7F6E6167DE0FQ36510326-27EFCDDC-6F6B-461B-8DC6-DC69A748F19FQ36591679-5961A964-86FA-4C9D-9461-21ACCA7F8981Q36677419-E679B875-FDF7-44C6-8E65-F6ACEE422B59Q36702201-4566D7CC-DE63-4DCC-83D3-5737BE714530Q36716920-49260E1C-9AED-42BE-9D92-7C32BB44D766Q37322650-F9DDEA85-F42E-4D38-B3B2-9D84C5859D8BQ37547547-5805F025-74E1-4CAB-9613-5A636E5BAB6DQ37679720-703F0F94-D7B5-4AF8-827D-4D35D6BFBD80Q37706587-5ADBA2B4-D17D-48A3-B227-AF81B9E379D9Q37945203-555AC6AB-B7A6-4320-BA65-6A2A24B6B258Q38028728-299FD6B4-89D2-4CD6-BA0E-66B292817FB5Q38255634-1892B1C5-F3C1-42F3-9534-B8A7218552E4Q38287790-F4F53E07-8455-4BE9-AFC9-762C6A54CFB1Q38603912-D7A6FFDC-83C7-4817-8450-EF93F81FEE98Q40102851-5F5B1178-583A-4F5B-B093-BBEC963001FE
P2860
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@ast
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@en
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@nl
type
label
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@ast
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@en
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@nl
prefLabel
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@ast
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@en
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@nl
P2093
P2860
P1433
P1476
Systemic, mucosal, and heterot ...... Norwalk virus-like particles.
@en
P2093
Boyd Yount
Christine Moe
Nancy Davis
Patrick R Harrington
Robert E Johnston
P2860
P304
P356
10.1128/JVI.76.2.730-742.2002
P407
P577
2002-01-01T00:00:00Z